USANA Health Sciences, Inc. (NYSE:USNA) Insider Daniel A. Macuga Sells 3,791 Shares

USANA Health Sciences, Inc. (NYSE:USNA) insider Daniel A. Macuga sold 3,791 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total transaction of $178,707.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

USANA Health Sciences Trading Down 3.3 %

Shares of NYSE:USNA opened at $45.55 on Friday. The stock has a market capitalization of $876.38 million, a PE ratio of 14.19, a P/E/G ratio of 1.43 and a beta of 0.94. USANA Health Sciences, Inc. has a 1 year low of $41.45 and a 1 year high of $69.60. The firm has a fifty day moving average price of $46.62 and a 200 day moving average price of $48.36.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.35. The firm had revenue of $221.08 million during the quarter, compared to analysts’ expectations of $206.70 million. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. On average, sell-side analysts forecast that USANA Health Sciences, Inc. will post 2.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

USNA has been the topic of several research analyst reports. DA Davidson lowered their price target on shares of USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating on the stock in a report on Thursday, February 22nd. StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, January 12th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in USANA Health Sciences by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,567,182 shares of the company’s stock worth $91,853,000 after acquiring an additional 38,533 shares during the last quarter. Pzena Investment Management LLC lifted its position in USANA Health Sciences by 3.1% during the 1st quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock worth $38,089,000 after acquiring an additional 23,729 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in USANA Health Sciences by 3.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company’s stock worth $36,323,000 after acquiring an additional 21,524 shares during the last quarter. Pacer Advisors Inc. lifted its position in USANA Health Sciences by 75.7% during the 4th quarter. Pacer Advisors Inc. now owns 337,371 shares of the company’s stock worth $18,083,000 after acquiring an additional 145,373 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in USANA Health Sciences by 4.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 222,423 shares of the company’s stock worth $11,922,000 after acquiring an additional 8,536 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.